G Mining Ventures Corp. Just Missed Earnings - But Analysts Have Updated Their Models
The analysts might have been a bit too bullish on G Mining Ventures Corp. (TSE:GMIN), given that the company fell short of expectations when it released its first-quarter results last week. Unfortunately, G Mining Ventures delivered a serious earnings miss. Revenues of US$95m were 14% below expectations, and statutory earnings per share of US$0.11 missed estimates by 48%. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
Following the latest results, G Mining Ventures' seven analysts are now forecasting revenues of US$523.7m in 2025. This would be a huge 115% improvement in revenue compared to the last 12 months. Per-share earnings are expected to shoot up 120% to US$0.89. In the lead-up to this report, the analysts had been modelling revenues of US$537.3m and earnings per share (EPS) of US$1.08 in 2025. The analysts seem less optimistic after the recent results, reducing their revenue forecasts and making a real cut to earnings per share numbers.
See our latest analysis for G Mining Ventures
The average price target climbed 5.6% to CA$25.33despite the reduced earnings forecasts, suggesting that this earnings impact could be a positive for the stock, once it passes. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values G Mining Ventures at CA$32.00 per share, while the most bearish prices it at CA$22.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the G Mining Ventures' past performance and to peers in the same industry. The analysts are definitely expecting G Mining Ventures' growth to accelerate, with the forecast 178% annualised growth to the end of 2025 ranking favourably alongside historical growth of 90% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 14% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that G Mining Ventures is expected to grow much faster than its industry.
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for G Mining Ventures. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for G Mining Ventures going out to 2027, and you can see them free on our platform here..
However, before you get too enthused, we've discovered 1 warning sign for G Mining Ventures that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
17 minutes ago
- UPI
Trump cancels U.S.-Canadian trade talks over tech taxes
Canadian Prime Minister Mark Carney meets with President Donald Trump in the Oval Office at the White House on May 6. Trump on Friday suspended trade talks due to Canada's new Digital Services Tax. File Photo by Francis Chung/UPI | License Photo June 28 (UPI) -- President Donald Trump cited potential Canadian taxes on U.S. tech companies as his reason for ending trade talks with Canada on Friday. The tech taxes on Amazon, Google, Meta and other U.S. tech firms are due on Monday, and Trump said it is a deal-breaker. "We have just been informed that Canada ... has just announced that they are putting a Digital Services Tax on our American technology companies," Trump said in a Truth Social post on Friday. He called the tax a "direct and blatant attack on our country" and accused Canada of "copying the European Union, which has done the same thing." "We are hereby terminating all discussions on trade with Canada, effective immediately," Trump said. His administration in the coming week will notify Canadian officials of the tariff that it will have to pay to do business in the United States, Trump added. Trump last week attended the G7 economic trade summit hosted by Canada and Canadian Prime Minister Mark Carney and sought common ground on trade talks, The Washington Post reported. Officials at U.S. tech firms oppose the Canadian tax, the amount of which is based on the revenues generated by Canadians' use of e-commerce sites, social media and the sales of data. All tech companies that generate more than $14.59 million from such services would be subject to the new 3% Digital Services Tax. The tax is retroactive to 2022 and could cost U.S.-based tech firms up to $3 billion, NBC News reported. Upon learning of Trump halting trade talks, Canadian officials on Friday limited U.S. steel imports and placed a 50% surcharge on steel imports that surpass the quota. Canadian Finance Minister Francois-Philippe Champagne said the surcharge will help to protect Canadian steel against what he called "unjust U.S. tariffs." He said the Canadian government is prepared to take additional actions, if necessary.
Yahoo
18 minutes ago
- Yahoo
Jeff Bezos and Lauren Sánchez are one of the richest married couples. Here's how the ultrawealthy do prenups.
With Jeff Bezos and Lauren Sánchez now married, they're likely to have a complex prenup. Lawyers and wealth management experts outlined the prenup process for the superrich. Business control, property ownership, and trusts are just some of the questions prenups tackle. Hindsight is 20/20 — especially when hindsight is worth $38 billion. Amazon founder Jeff Bezos and MacKenzie Scott, his first wife, got married without a prenup (in 1993, before Bezos started Amazon). Scott received roughly $38 billion in Amazon shares in the settlement, making her one of the world's richest women. On Friday, Bezos got married again, this time to helicopter pilot and former journalist Lauren Sánchez. Experts in family law and wealth management told Business Insider that the couple is almost certain to have a complex prenup. Bezos is, after all, worth more than $200 billion today. A representative for Bezos didn't respond to a request for comment from BI about whether the couple has a prenup. Anne Paape, the managing director and head of wealth strategy at Cresset Capital, a multi-family office for entrepreneurs and multi-generational families of wealth, said prenups are generally becoming more common and are sometimes even mandated in family trusts for the ultrawealthy. Prenups begin with both people fully disclosing their financial assets and debts, she said. Besides family, they can also involve everyone from business partners and tax attorneys to luxury realtors and aviation experts who help appraise homes and private jets, said Brooke Summerhill, a divorce financial consultant who primarily works with ultra-high net worth clients. "It's not the clients making a lot of these decisions, it's their team helping them understand what those decisions are and making those decisions with them," she told BI. Paape doesn't know the details of Bezos' potential prenup but said his situation isn't entirely unique: Many superrich weddings mark second or third marriages for at least one spouse, often one whose assets have changed considerably since their first time tying the knot. "He will absolutely have protection against anything that he could," Summerhill said, adding that he likely won't let his pre-marriage assets co-mingle with Sánchez's assets. The more money you have, the more potential prenup headaches you'll have, especially when it comes to business interests and properties. Wealthy clients tend to have properties and business interests around the globe, making it harder to ensure compliance with divorce and death laws in various jurisdictions. Many entrepreneurs like Bezos are focused on insulating their businesses in the event of a divorce or death. Most don't want to risk giving an ex-partner enough stock to have a say in how the company runs, Paape told BI. "You could try to compensate for keeping that off the table," Paape said. "What else if you were to get divorced? What other resources could you provide to that person?" Clauses safeguarding the appreciation of assets during a marriage are also key for wealthy clients, Summerhill said. If the couple ever divorces, it's not unlikely that Sánchez would get a lump sum, Amazon shares, and some real estate, according to Summerhill and Raymond Hekmat, a family law attorney in Beverly Hills who primarily writes prenups. But a marriage can also end in death, and that's where a death clause can come in. As Summerhill put it, this "prevents the surviving spouse from claiming a bigger portion of that deceased person's separate property." A surviving spouse commonly receives a lump sum or life insurance payout upon their spouse's death, she said, but a last will and testament may take precedent over the prenup. Prenups for the ultrawealthy have repercussions beyond the couple, whether it's about who takes over the family empire or gets the keys to the Hamptons home. "There's more people that care about the resolution of that breakup, whether it's divorce or death," Paape said. "It's business partners, it's employees, it's charities you support, it's children and grandchildren." She said trusts "are a no-brainer " for children of the ultrarich and that many provisions deal with inherited property or business ownership. Bezos shares four children with Scott, and Sánchez has three kids. Hekmat said all the prenups he draws up have a confidentiality provision, and some can include social media restrictions. "In the event of a breakup, you can't disparage the other party or discuss the prenup in any way with the public, and there could be penalties involved," he said. Prenups can also include sunset clauses, which say that some provisions or even the full agreement expires after a certain period of time. Some people may choose to change certain provisions and become more generous after they've been with their spouse for a while, Paape said. Hekmat said that even with prenups, couples risk messy legal and financial fights down the line. Proclaimed love and devotion aside, he kept his advice for the Bezoses of the world simple. "My bottom line for billionaires is don't get married." Have a tip or a story to share about your own experiences with a prenup? Contact these reporters via email at atecotzky@ or sjackson@ or on Signal at alicetecotzky.05. Use a personal email address and a nonwork device; here's our guide to sharing information securely. Read the original article on Business Insider
Yahoo
21 minutes ago
- Yahoo
Is Danaher's M&A Premium Already Priced In?
Danaher Corporation (NYSE: DHR) is a global science and technology innovator focused on designing, manufacturing, and marketing professional, medical, industrial, and commercial products and services. Following the 2023 spin-off of its Environmental & Applied Solutions segment (now Veralto), Danaher has transformed into a pure-play life sciences and diagnostics company, operating through three primary segments: Biotechnology, Life Sciences, and Diagnostics. Warning! GuruFocus has detected 4 Warning Signs with DHR. Biotechnology (~30% of FY2024 revenue) includes Danaher's bioprocessing and genomic reagents businesses, led by brands like Cytiva and Pall, serving pharmaceutical and biotech companies in biologics production and Sciences (~25% of revenue) offers analytical instruments, microscopy, and lab automation tools used by academic institutions, research labs, and clinical diagnostics developers. Key platforms include Leica Microsystems, SCIEX, and Beckman Coulter Life (~45% of revenue) comprises molecular diagnostics, core laboratory diagnostics, and point-of-care testing systems. Notably, Cepheidone of Danaher's flagship brandsoffers rapid molecular diagnostic testing platforms, particularly for infectious diseases like COVID-19, influenza, and tuberculosis. Danaher reported a better-than-feared quarter, beating both top and bottom line estimates significantly and maintaining its annual guidance. In Q1 FY2025, the company's total sales declined by 1% YoY to $5,741 million from $5,796 million in the previous year's quarter. The decline was due to -1.5% impact from foreign exchange translation, which was partially offset by 0.5% growth through acquisitions and flat core revenue growth. The revenue from the Biotechnology segment grew by 6% YoY to $1,612 million, driven by an increase in core sales from high-growth markets due to a rise in demand. The Life Sciences segment saw a decline of 3.5% YoY to $1,680 million due to a decrease in core sales in the genomics consumables business. Revenue from the Diagnostics segment declined by 3% YoY to $2,449 million due to a decline in the sales of the molecular diagnostic business and lower sales in the China region. The adjusted operating profit declined by 50 bps YoY to 29.6% in the quarter due to product mix, administrative cost structure, currency exchange rates, and acquisition Corporation's Growth & Cash Flow Danaher is positioned as a leading provider of life sciences, diagnostic, and biotechnology equipment after spinning off its environmental business (Veralto) in late 2023. Management's guidance for FY2025 assumes relatively stable end-market demand for the rest of the year (similar to Q1 levels). Against this backdrop, I believe Danaher should grow modestly in 2025, reflecting both macro headwinds (tariffs, academic budget cuts) and continued strength in critical segments. I have mentioned the guidance provided by the management below, and my thesis that should help the company achieve it. For fiscal 2025, Danaher reaffirmed core revenue growth of roughly +3% year-over-year. This is consistent with management's view that market demand (globally) will be relatively consistent with Q1, despite tariffs and other pressures. Adjusted diluted EPS guidance was set at $7.60$7.75 (vs. $7.68 consensus). Notably, management raised its Bioprocessing (biotech) growth forecast to the high-single-digits for 2025 (from a prior 67% outlook). Bioprocessing is Danaher's fastest-growing segment. Robust demand for biologic drug development kits and reagents drove higher Q1 results and should continue to drive growth for the remainder of FY2025. Furthermore, the segment is emerging from the destocking cycle, which should help drive sales. In contrast, the Life Sciences segment forecast was trimmed to essentially flat growth, as funding uncertainties slowed academic and government sales (particularly in the U.S.), and China's medical equipment sector has experienced some softness. This should offset the healthy growth in the Bioprocessing segment. However, any rebound in global R&D spending (or continued Chinese stimulus) could surprise on the upside. The Diagnostics segment (especially Cepheid's molecular tests) is expected to see modest growth: Cepheid's respiratory test sales are forecast to reach around $1.7 billion for 2025, but production volume will return to a normal seasonal level after Q1. Overall, Danaher's portfolio remains tilted toward high-growth medical and diagnostics markets, which underpins its steady outlook despite industry headwinds. A key uncertainty is trade policy: Danaher estimates that current U.S. and European tariffs could add roughly $350 million in costs in 2025. However, the company has long worked to offset these costs via its Danaher Business System (DBS), regionalized manufacturing, and pricing strategies. The company should absorb much of the tariff impact through cost actions and supply-chain adjustments (e.g., surcharges or shifting production) rather than curtailing R&D or major initiatives. Because Danaher's products (lab instruments, diagnostics, and biotech consumables) are often mission-critical in healthcare, I believe its end markets will remain resilient even under tariff pressure. In short, tariffs represent a moderate headwind, but Danaher should largely neutralize the impact by expense reductions and operational flexibility. Margins in the upcoming quarters are expected to contract largely due to seasonality in Cepheid's respiratory testing business. Cepheid is one of Danaher's higher?margin units, and Q2 respiratory kit revenue is assumed to be only about $250 million (vs. ~$625 million in Q1). This sharp seasonal drop in high-margin sales, plus normal diagnostic restructuring costs (e.g., the management of China's reimbursement changes), drives the lower quarter?on?quarter profit margin. In sum, I believe the company's margins should continue to decline and improve in the back half of 2025. As a company built on decades of disciplined capital deployment, Danaher's ability to acquire and successfully integrate businesses has been one of its defining competitive advantages. Flagship acquisitions like Cepheid and Pall have meaningfully strengthened Danaher's diagnostics and bioprocessing platforms, but they also introduce inherent integration risks. These include short-term pressures on margins, incremental R&D and SG&A costs, and the complexities of aligning acquired operations with Danaher's operating structure. While such challenges are typical of any acquisitive strategy, Danaher's track record sets it apart. Over the past 30 years, the company has repeatedly demonstrated its ability to extract synergies, improve productivity, and scale acquisitions effectively, largely driven by the Danaher Business System (DBS). This system institutionalizes continuous improvement, cost efficiency, and cultural integration across its portfolio. Though former CEO Larry Culp played a pivotal role in establishing this M&A discipline, the company's current leadership remains strongly committed to DBS principles, which continue to guide its post-acquisition integration efforts. Moreover, Danaher doesn't pursue acquisitions purely for scale; it focuses on high-quality, strategic assets that complement existing platforms and offer long-term value creation. While integration may temporarily weigh on profitability, especially in the form of restructuring expenses, near-term dilution, or elevated investments in innovation, these are often calculated trade-offs for future operating leverage and market expansion. In essence, what might be viewed as a risk is also one of Danaher's greatest strengths; its consistent ability to turn acquired assets into high-margin, growth-focused businesses that reinforce its leadership in life sciences and diagnostics. As of March 31, 2025, investor activity around Danaher reflected a balanced mix of strategic repositioning and continued confidence in the company's long-term potential. Notably, renowned value investors like Joel Greenblatt (Trades, Portfolio) (+29.03%), Wallace Weitz (Trades, Portfolio) (+23.17%), and Arnold Van Den Berg (Trades, Portfolio) (+14.62%) significantly increased their holdings, signaling optimism about Danaher's focused life sciences and diagnostics trajectory. Ken Fisher (Trades, Portfolio) also added modestly to his position (+1.23%), reinforcing steady institutional support. While some investors like Jefferies Group (Trades, Portfolio), Mario Gabelli (Trades, Portfolio), and George Soros (Trades, Portfolio) trimmed their stakes. Danaher is currently trading at a forward P/E of 25.5x and 22.9x on FY2025 and FY2026 estimated EPS of $7.70 and $8.57, respectively, which is below its five-year average forward P/E of 29.9x. On an EV/EBITDA basis, Danaher trades at approximately 18xhigher than peers such as Thermo Fisher Scientific (P/E ~15x, EV/EBITDA ~13x) and Agilent Technologies (P/E ~21x, EV/EBITDA ~15x). While Danaher's valuation premium may appear elevated relative to peers, it reflects the company's consistent execution, higher exposure to recurring revenue from consumables, and strong margin profile. The market seems cautiously optimistic, pricing in steady growth expectations. For FY2025, Danaher's outlook implies stable and controlled expansion, led primarily by strong bioprocessing demand. Although adjusted operating margins are expected to decline in Q2 due to seasonal normalization in the high-margin Cepheid business, a recovery is anticipated in the latter half of the year. Danaher's long-standing execution discipline, anchored by the Danaher Business System (DBS), equips it to offset macro pressures through operational efficiency and agile supply chain management. With a focused portfolio in mission-critical life sciences and diagnostics, Danaher remains well-positioned to deliver modest yet resilient growth in 2025, supported by strategic capital deployment and a strong competitive moat. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
